Disease · MONDO_0006115

blast phase chronic myelogenous leukemia, BCR-ABL1 positive

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. blast phase chronic myelogenous leukemia, BCR-ABL1 positive. Diseases, record MONDO_0006115. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006115

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Open Targets
Open Targets ID: MONDO_0006115; Open Targets
Other names: blast crisis, blast phase CML, blast phase chronic granulocytic leukaemia, blast phase chronic granulocytic leukemia, blast phase chronic myelocytic leukaemia, blast phase chronic myelocytic leukemia, blast phase chronic myelogenous leukaemia, blast phase chronic myelogenous leukemia, blast phase chronic myeloid leukaemia, blast phase chronic myeloid leukemia, blastic phase CML, blastic phase chronic granulocytic leukaemia, blastic phase chronic granulocytic leukemia, blastic phase chronic myelocytic leukaemia, blastic phase chronic myelocytic leukemia, blastic phase chronic myelogenous leukaemia, blastic phase chronic myelogenous leukemia, blastic phase chronic myeloid leukaemia, blastic phase chronic myeloid leukemia; Open Targets
MeSH: D001752; MeSH
NCI Thesaurus: C9110; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 6 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EDETATE CALCIUM DISODIUM ANHYDROUS	CHEMBL1200375	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MOLGRAMOSTIM	CHEMBL2109134	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
REGRAMOSTIM	CHEMBL2107881	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
SUCCIMER	CHEMBL1201073	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
DACTOLISIB	CHEMBL1879463	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF2RA	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1438	Drugs and targets
CSF2RB	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1439	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 2	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 2	https://conductscience.org/library/genes/3455	Drugs and targets
MTOR	Serine/threonine-protein kinase mTOR	1	Serine/threonine-protein kinase mTOR inhibitor	Phase 1	https://conductscience.org/library/genes/2475	Drugs and targets
PIK3CA	PI3-kinase class I	1	PI3-kinase class I inhibitor	Phase 1	https://conductscience.org/library/genes/5290	Drugs and targets
PIK3CB	PI3-kinase class I	1	PI3-kinase class I inhibitor	Phase 1	https://conductscience.org/library/genes/5291	Drugs and targets
PIK3CD	PI3-kinase class I	1	PI3-kinase class I inhibitor	Phase 1	https://conductscience.org/library/genes/5293	Drugs and targets
PIK3CG	PI3-kinase class I	1	PI3-kinase class I inhibitor	Phase 1	https://conductscience.org/library/genes/5294	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00548847	Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation	Phase 2	15	2016-08-18	Leukemia	INTERFERON ALFA-2B, REGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT06811233	Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study	Phase 2	140		Acute Myeloid Leukemia (AML)	EDETATE CALCIUM DISODIUM ANHYDROUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT01756118	A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia	Phase 1	24		Acute Lymphoblastic Leukemia, Leukemia, Myelocytic, Acute, Chronic Myelogenous Leukemia With Crisis of Blast Cells	DACTOLISIB	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
32993794	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006115

GET https://conductscience.org/api/diseases/v1/MONDO_0006115/drugs

API reference For AI assistants